Why Should You Attend:
The European Commission has passed and published the final version of Annex 13 ("Investigational Medicinal Products") to the EC GMP Guide. The new Annex comes into force in July 2010. It calls for special attention in areas to GMP conformity for investigational medicinal product by personnel working on clinical trials. Compliance can be achieved especially thorough training, some possible changes in processes and revision of some GMP standard operating procedures. These enhanced requirements reflected in the revision of Annex 13 are part of the strict regulations now in force in the European Community.
The session will review the guideline to cover the key areas of compliance including: The role of the "Qualified Person", Packaging, labeling, reconciliations that should take place for each product and each production stage, and Comparator product requirements etc.
Areas Covered in the Seminar:
- Review the role of the "Qualified Person" who must have access to the Product Specification File as the basis for assessment of the suitability for release and certification of a particular batch.
- Packaging instructions requires expressly with a view to the complicated procedures in the manufacture of investigational medicinal products.
- The requirement for reconciliation at the end of the packaging and labelling processes.
- Packaging materials requires special quality control checks for a homogeneous appearance of the packs in order to prevent unintentional unblinding due to a visible difference between the placebo and the active medication packs.
- Manufacturing operations that the production parameters and the corresponding in-process controls must be deduced from the knowledge actually available at the time.
- An appropriate process of blinding the test preparation, comparator product and placebo must be completely identifiable.
- The requirements for the randomisation procedure are also more strictly formulated: in addition, safety aspects and the procedure for breaking the code must be described in the corresponding procedures.
- The section on the risks of product mix up in the case of simultaneous packaging of different preparations.
- Labelling is specifically detailed in the draft e.g.
name, address and telephone number of the sponsor, contract research organisation or the principal contact for the clinical trial.
Who Will Benefit:
This webinar will provide valuable assistance to all companies/ manufacturing sites. Those that would benefit most would be:
- Clinical Research Professionals
- Clinical Research Project Managers
- Technical Directors / VP's
- Operations / Production Managers
- Quality Assurance Managers
- SOP mangers and co-ordinators
For More Details: